MK 991 - A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475)Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone
More Details...
A Phase 3, Randomized, Double-Blind study of Pemrbrolizumab plus Docetaxel plus prednisone versus Placebo plus Docetaxel Plus Prednisone.
More Details...
Genomic Health- A Retrospective Multicenter Study to Assess Treatment Decisions and Outcomes for NCCN Favorable Intermediate Risk Patients After Receiving the Oncotype DX Genomic Prostate Score Result
More Details...